Bapineuzumab
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) [1][2].
Product Specifications
CAS Number
[648895-38-9]
UNSPSC
12352203
Target
Amyloid-β
Type
Inhibitory Antibodies
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/bapineuzumab.html
Purity
96.62
Solubility
10 mM in DMSO
Smiles
[Bapineuzumab]
Molecular Weight
(144.5 kDa)
References & Citations
[1]Stephen Salloway, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370 (4) :322-33.|[2]Fuller, J. P., et al., (2015) . Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies. Acta neuropathologica, 130 (5), 699–711.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items